Cyclo Therapeutics Correlations
CYTH Stock | USD 0.62 0.01 1.64% |
The correlation of Cyclo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Cyclo Therapeutics Correlation With Market
Good diversification
The correlation between Cyclo Therapeutics and DJI is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cyclo Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Cyclo |
Moving together with Cyclo Stock
Moving against Cyclo Stock
0.49 | DYAI | Dyadic International | PairCorr |
0.4 | ESPR | Esperion Therapeutics | PairCorr |
0.32 | PTN | Palatin Technologies | PairCorr |
0.34 | MNMD | Mind Medicine | PairCorr |
0.36 | TOVX | Theriva Biologics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cyclo Stock performing well and Cyclo Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cyclo Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ATNX | 13.35 | (4.40) | 0.00 | (1.00) | 0.00 | 25.00 | 143.13 | |||
MMNFF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
LFCR | 3.10 | 0.56 | 0.14 | 0.49 | 3.65 | 8.08 | 20.91 | |||
LSDI | 298.43 | 161.12 | 3.23 | (1.75) | 27.98 | 550.00 | 3,998 | |||
GHSI | 5.47 | 0.88 | 0.06 | (0.37) | 8.11 | 18.66 | 101.05 | |||
AGRX | 3.20 | (1.17) | 0.00 | (5.48) | 0.00 | 7.63 | 19.82 | |||
TKNO | 4.64 | 0.96 | 0.20 | 0.70 | 4.55 | 12.84 | 32.06 | |||
PTPI | 4.31 | 0.28 | 0.03 | 7.04 | 4.22 | 12.90 | 45.54 | |||
PAHC | 1.67 | 0.05 | 0.05 | 0.15 | 1.56 | 3.70 | 10.13 | |||
SHMN | 5.56 | (0.57) | 0.00 | 0.76 | 0.00 | 11.11 | 38.18 |
Cyclo Therapeutics Corporate Management
Michael Lisjak | Global Development | Profile | |
Lise MD | Chief Officer | Profile | |
George Fails | Ex Mang | Profile | |
Jeffrey Tate | Chief COO | Profile | |
Scott Fine | CEO Director | Profile | |
Lori McKenna | Global Advocacy | Profile | |
E Strattan | Founder Director | Profile |